Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Supply chain

Health secretary asked for list of medicines at risk under 'no-deal' Brexit

Health and social care secretary Matt Hancock


Health and social care secretary Matt Hancock (pictured) has received a letter from Sarah Wollaston, chair of the House of Commons health and social care committee, in which she asks what measures are being put in place in case of supply issues after a ‘no-deal’ Brexit

Sarah Wollaston, chair of the House of Commons health and social care committee, has written to health and social care secretary Matt Hancock to ask him to publish a list of medicines and medical products that have been identified as at risk of supply issues in the case of a ‘no-deal’ Brexit.

In a letter to Hancock, dated 21 November 2018, Wollaston asks that the published list sets out clearly any medicines that cannot be switched without creating additional risk to patients and where careful review would be required, and the contingency plans that the Department of Health and Social Care is putting in place.

The letter expresses the committee’s concerns over a no-deal scenario in terms of patient access to medicines and medical products, the costs of contingency planning, and non-disclosure agreements.

Wollaston also asks for clarification on the rationale behind requesting companies to sign non-disclosure agreements, and for more information about the content of the agreements. She says that while non-disclosure agreements may be appropriate to protect the commercial interests of the companies involved, the committee was concerned that they might pose a barrier to the disclosure of information that may be in the public interest.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205806

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.